Here we describe a method for the engineered regulation of protein kinases in living cells, the design and application of RapR (rapamycin regulated) kinases. The RapR kinase method enables activation of kinases with high specificity and precise temporal control. Insertion of an engineered allosteric switch, the iFKBP domain, at a structurally conserved position within the kinase catalytic domain makes the modified kinase inactive. Treatment with rapamycin or its non-immunosuppressive analogs triggers interaction with a small FKBP-rapamycin-binding domain (FRB), restoring the activity of the kinase. The reagents used in this method are genetically encoded or membrane permeable, enabling ready application in many systems. Based on the structural similarity of kinase catalytic domains, this method is likely applicable to a wide variety of kinases. Successful regulation has already been demonstrated for three kinases representing both tyrosine and serine/threonine kinase families (p38, FAK, Src). Procedures for designing and testing RapR kinases are discussed.
INTRODUCTION
Protein kinases comprise nearly 2% of the human genome (Manning et al., 2002) . Phosphorylation of proteins by kinases is a key regulatory step in virtually all essential processes in mammalian cells. A substantial number of kinases are implicated in the development and progression of human diseases. Hence, kinases are the subject of extensive biological studies, and in many cases are targets for therapeutic treatment. Manipulation of the catalytic activity of kinases provides an important opportunity to understand the role of these key players in a broad range of important signaling pathways.
The most common methods for manipulation of kinase activity include overexpression of mutants, application of pharmacological inhibitors, and down-regulation of kinase expression by siRNA or genetic modifications. Down-regulation and overexpression of kinases enable targeted control, but do not provide temporal control. Application of pharmacological inhibitors allows excellent temporal control, but is often not sufficiently specific. An elegant method developed by Shokat overcomes the problem of kinase inhibitor specificity by utilizing mutant kinases that can be specifically targeted by modified analogs of the existing inhibitors (Bishop et al., 2001) . In contrast to these methods, the RapR approach combines specificity, temporal control, and activation rather than inhibition.
Several approaches have been used for activation of kinases in living cells, but their applications are limited to specific cases. For certain receptor tyrosine kinases, activation has been achieved by drug-induced dimerization of the kinase (Spencer et al., 1993) . Alternately, the activity of a specifically designed kinase mutant can be rescued by treatment with imidazole or its analogs (Qiao et al., 2006) . The method provides very specific and reversible activation, but its design is limited to the tyrosine kinase family HEK293T cells co-expressing myc-tagged RapR-FAK and GFP-FRB were treated with 200 nM rapamycin for the indicated period of time. The kinase was immunoprecipitated and its activity was tested using the N-terminal fragment of paxillin as a substrate. Phosphorylation level of paxillin on Tyr31 indicates the activity of FAK. Reprinted with permission from Karginov et al. (2010a) .
and requires treatment with a high concentration (5 mM) of imidazole. The RapR method enables specific activation of a broad variety of kinases with temporal control in living cells.
We make use of the well characterized rapamycin-mediated heterodimerization of small FK506-binding protein (FKBP12) and an FKBP12-rapamycin-binding (FRB) domain of mTOR. The advantages of this system include tight and quick regulation of complex formation, use of genetically encoded and membrane permeable reagents, the small size of FKBP12 and FRB tags (90 to 120 amino acids), and the availability of non-immunosuppressive analogs of rapamycin. A growing number of studies have The red arrows points to the G-loop, critical for catalytic activity. iFKBP was placed in the insertion loop of FAK wt to generate RapR-FAK. The mobility of the iFKBP was transmitted to the G loop, rendering it sensitive to rapamycin/FRB binding. Reprinted with permission from Karginov et al. (2010a) . For the color version of this figure go to http://www.currentprotocols.com/protocol/cb1413. HEK293T cells co-expressing the indicated flag-tagged p38α construct and GFP-FRB were treated with either 200 nM rapamycin or ethanol solvent control. The kinase activity of p38α was tested in vitro using ATF2 as a substrate. Reprinted with permission from Karginov et al. (2010a) . demonstrated successful application of this dimerization approach for experiments in live cells and in animal models (Spencer et al., 1993; Rivera et al., 1999; Stankunas et al., 2003; Inoue et al., 2005) . To achieve regulation of kinases, we created a modified FKBP12 protein suitable for insertion into the middle of other proteins (insertable FKBP, or iFKBP; Fig. 14.13 .1), and used it as an allosteric switch to regulate the catalytic activity of focal adhesion kinase (FAK; Karginov et al., 2010a) . Insertion of iFKBP into a structurally conserved portion of the kinase catalytic domain rendered FAK inactive. Importantly, this modification did not affect FAK's localization or its interaction with binding partners. The catalytic activity of FAK was rapidly restored upon interaction with rapamycin and co-expressed FRB protein (Fig. 14.13 .2). Molecular modeling and structure-activity studies indicated that the rigidity of a critical G-loop in the catalytic domain is decreased due to the high dynamic mobility of the inserted iFKBP domain, disrupting kinase activity. Binding to rapamycin and FRB significantly reduced the mobility of iFKBP, restoring the stability of the G-loop and catalytic activity of the kinase (Fig. 14.13 Figure 14 .13.5 Light-mediated activation of a protein kinase. (A) Myc-RapR-FAK kinase was co-expressed with GFP-FRB in HEK293T cells. Cells were treated with the indicated amount of rapamycin (Rap), caged rapamycin (pRap), or DMSO (control). The indicated samples were exposed to UV light (365 nm, 1 min). All cells were incubated at 37
• C for 1 hr after treatment. Myc-RapR-FAK was immunoprecipitated using an anti-myc antibody and tested in a kinase assay using an N-terminal fragment of paxillin as a substrate. The level of phosphorylation of paxillin on Tyr31 indicates kinase activity. (B) HeLa cells co-transfected with GFP-RapR-FAK and Cherry-FRB were treated with pRap (1 μM) and imaged before and after UV irradiation (365 nm, 1 min).
Arrows indicate formation of large dorsal ruffles stimulated by activated RapR-FAK. Reprinted with permission from Karginov et al. (2010b) . Copyright (2010) American Chemical Society.
large dorsal protrusions, a novel finding that suggested a new mechanism for FAK involvement in tumorigenesis. We have shown that RapR FAK can also be regulated by non-immunosuppressive analogs of rapamycin (iRap and AP21967), demonstrating its potential for experiments in animals. The site of iFKBP insertion is structurally conserved among all kinases, suggesting that the new approach can be broadly applied. This was supported by the successful development of rapamycin-regulatable variants of the tyrosine kinase Src, and a serine/threonine kinase p38α (Fig. 14.13.4) . In collaboration with Dr. A. Deiters at North Carolina State University, we have recently developed a "caged" rapamycin molecule, in which an o-nitrobenzyl photocleavable protecting group inactivates the molecule until it is irradiated (Karginov et al., 2010b) . The caged rapamycin had no effect on RapR-FAK until treatment with 360-nm light, which generated FAK-mediated dorsal ruffles (Fig. 14. 13.5) (Karginov et al., 2010b) . Here, we describe methodology for design and development of RapR-kinases using FAK as an example.
Multiple alternatives strategies to clone iFKBP into the kinase can be conceived. Here we present a method that has been used successfully to generate all of our RapR-kinases. This strategy is based on a known site-directed mutagenesis approach. Unlike more traditional strategies, this method does not require any unique restriction sites for cutting at the site of insertion or for subsequent ligation of DNA fragments. Therefore, this method has no specific sequence requirements for the insertion site and enables creation of any linkers between the catalytic domain and FKBP in one cloning step.
STRATEGIC PLANNING
One of the key requirements for the development of a RapR kinase is the availability of a reliable method to test the activity of the targeted kinase. The method we used for FAK requires in vitro assessment of kinase activity after immunoprecipitation from cell extract. Each kinase assay must be optimized on a case-by-case basis. The conditions described here were optimized for FAK.
The assays we used were based on immunoprecipitation using myc and FLAG tags. These were placed at the N-terminus of FAK and p38. However, due to lipid modification of Src at the N-terminus, it had to be tagged at the C-terminus. A tag is not necessary as long as the kinase can be immunoprecipitated using a kinase-specific antibody and its activity can be tested in vitro. With untagged kinases, immunoprecipitation of endogenous kinases may elevate background levels of kinase activity in the assay. We have chosen to apply the RapR approach to constitutively active kinases. This insures that kinase activity is strictly under the control of the experimentalist, and not subject to regulation by endogenous signaling pathways. In some studies, it may be valuable to activate wild-type, regulated kinase.
For the actual design of the RapR kinase, it is very helpful to have a crystal structure of the targeted kinase's catalytic domain. A crystal structure can guide identification of the position for insertion of iFKBP. If necessary, the crystal structure of a close homolog can suffice, or the position for insertion of iFKBP can even be deduced through comparison of the targeted kinase sequence to sequences of nonrelated kinases.
Selection of the insertion site for iFKBP is based on the fact that the catalytic domain structure for all members of the eukaryotic protein kinase (ePK) superfamily is very similar. As depicted in Figure 14 .13.6, the iFKBP is positioned in the conserved structure we call the "insertion loop." This is in the β-sheet structured N-terminal lobe of the catalytic domain, a loop opposite the G-loop described in published studies as a critical structural element of all ePKs (Krupa et al., 2004) . If a structure of the targeted catalytic domain is unavailable, one can identify the insertion loop by comparing its amino acid sequence to a protein kinase with known structure. Due to the high degree of conservation, this can be accomplished even by comparison with unrelated kinases. By comparing the amino acid sequences of the tyrosine kinase Src and the serine/threonine kinase p38, we could readily identify the site for insertion of iFKBP (Fig. 14.13.7) . Our experiments demonstrated that insertion of iFKBP at the selected site led to successful generation of both RapR-Src and RapR-p38 (Fig. 14.13.4).
Once the insertion loop is identified, several alternative construct designs can be considered for insertion of iFKBP into the loop. The iFKBP can replace either one amino acid in the loop, or the entire insertion loop (Fig. 14.13.8) . For FAK, replacing one amino acid in the middle of the loop was not sufficient for tight regulation (Fig. 14.13.8) . Replacement of the entire insertion loop (Met442-Ala448) with iFKBP created the optimal constructs (Fig. 14.13.8B). Our studies indicate that replacing the insertion loop with iFKBP using no linkers eliminates the ability of iFKBP to regulate the catalytic domain, and to bind rapamycin and FRB (Fig. 14.13.8).We have had success with two linkers that were tested when generating RapR-FAK: a short Gly linker and a longer Gly-Pro-Gly. The short linker may work better for iFKBP insertion, replacing only one amino acid in the loop, whereas the longer linker is likely to prove optimal for replacement of the entire insertion loop with iFKBP.
As a general rule, if a single amino acid replacement is chosen, we recommend replacing the amino acid in the middle of the insertion loop. Ideally, the replaced amino acid should be either polar or small (i.e., Glu, Arg, Lys, Gly). Unlike hydrophobic amino acids, such amino acids are more likely to be exposed to solvent.
Another key criterion for iFKBP insertion is involvement of the insertion loop in any known interactions. Insertion of iFKBP into an existing binding site for another protein will likely affect regulation of some of the pathways mediated by the kinase. In the case of FAK, Src, and p38, no known interactions involve the insertion loop.
It is important to generate kinase inactive control constructs to test RapR kinase specificity and kinase control in vitro and in vivo. The most common inactivating mutation is replacement of a critical Lys residue in the N-terminal lobe of all catalytic kinases (Lys454 in mouse FAK). However, this residue is in the β-strand directly connected to
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Current Protocols in Cell Biology Supplement 53 the iFKBP insertion. Since both the mutation of the Lys and the insertion of iFKBP are potentially destabilizing, introducing both in such close proximity may substantially affect the catalytic domain structure. Thus, we recommend using a different inactivating mutation. A critical Asp residue in the C-terminal lobe of the catalytic domain (catalytic base) is present in all ePKs (Asp546 in mouse FAK) and is essential for the phosphate transfer reaction (Krupa et al., 2004) . Mutation of this residue to Arg will efficiently abrogate catalytic activity, and will be sufficiently distanced from the iFKBP insertion site. We used this particular mutation in RapR-FAK and RapR-Src to create "kinase dead" controls (Karginov et al., 2010a) .
GENERATION OF KINASE CONSTRUCTS WITH iFKBP INSERTION
The cloning method described here is based on the same principle as the QuikChange site-directed mutagenesis kit provided by Agilent Technologies, Inc. Although reagents from different sources can be used for this procedure, here we describe a basic protocol using reagents provided by Agilent. The strategy involves two steps (Fig. 14.13 .9).
Generation of a "megaprimer" for insertion of iFKBP
Generation of a "megaprimer" encoding the iFKBP insert is accomplished by PCR and requires a specific set of primers. The primers for the "megaprimer" synthesis contain three critical parts (Fig. 14.13.9) . First, each primer should contain a 20-to 25-nucleotide portion that will anneal at either 5 or 3 ends of iFKBP. This is required for synthesis of iFKBP DNA by PCR. Second, immediately adjacent to this should be fragments encoding linkers that will connect iFKBP to the catalytic domain of the kinase. Finally, the primers should be flanked by 28-to 32-nucleotide regions that will anneal either before or after the insertion site in the kinase gene (Fig. 14.13 .9). As described above, the iFKBP insertion site in the catalytic domain of a kinase can be identified either by kinase structure analysis or by comparison with other kinases with known structure. Here we provide two examples of primers used for insertion of iFKBP into the FAK catalytic domain, using two different linkers and representing the two alternative insertion options (replacing one amino acid or replacing the entire insertion loop; see above; Fig. 14.13 .10). The resulting synthesized "megaprimer" DNA duplex will contain the iFKBP insert flanked by the linker sequences and the long kinase annealing sites required for site-directed insertion (Fig. 14.13.9 ).
Insertion of iFKBP by site directed mutagenesis PCR
In the next step, perform PCR using the generated "megaprimer" DNA duplex and the template vector bearing the gene of the targeted kinase, to synthesize a modified DNA construct with iFKBP insertion (Fig. 14.13.9 ). The template plasmid can be efficiently removed by subsequent digestion with DpnI enzyme that selectively digests only methylated DNA. This will significantly increase the yield of the modified construct. Identification of the clones with iFKBP insertion can be accomplished through PCR colony screening using a set of primers that will anneal in the template DNA construct and in the insert (Sandhu et al., 1989) . Such a combination of primers will generate product only from colonies that contain constructs with an iFKBP insert.
Below, we describe a procedure for generation of two different variants of FAK with iFKBP insertion. This strategy can be easily adapted for insertion of iFKBP into any other kinase.
Materials
DNA primers for iFKBP "megaprimer" synthesis ( Fig. 14 (Kramer and Coen, 2001 ) and PCR screening of obtained colonies (Sandhu et al., 1989) Day 1: Generation of "megaprimer" encoding iFKBP insert 1. For each insert, conduct a PCR reaction (Kramer and Coen, 2001 ) using DNA primers for iFKBP "megaprimer" synthesis and pmyc-iFKBP-FAK construct as a template. For PfuTurbo DNA polymerase, use reagents and reaction conditions recommended by Agilent Technologies. Analyze and purify the resulting PCR product by DNA gel electrophoresis using either previously described procedures or commercial kits (e.g., Qiagen DNA gel purification kit); the size of the PCR product should be approximately 400 base pairs. Dissolve the purified "megaprimer" DNA fragment in water. 4. After completion of the PCR reaction, add 1 μl of DpnI enzyme and incubate the mixture at 37 • C for 1 to 1.5 hr. Transform 1 to 2 μl of the PCR reaction into DH5α competent cells following the manufacturer's protocols or using other suitable conditions. Plate transformed bacteria on LB agar plate with appropriate antibiotic for selection (50 μg/ml of carbenicillin for pmyc-FAK expression construct). Incubate plate at 37 • C overnight. Day 2: Insertion of iFKBP into the FAK gene 5. Perform a PCR screen of obtained colonies as described previously (Sandhu et al., 1989) . (Fig. 14.13 6. Once positive clones are identified, inoculate one positive colony into 50 ml of LB liquid medium with appropriate selection antibiotic (50 μg/ml carbenicillin for the pmyc-FAK based constructs) and incubate at 37 • C overnight.
Use a set of primers that will anneal in the template vector and in the insert
Day 3: Insertion of iFKBP into the FAK gene 7. Prepare plasmid DNA from the 50-ml overnight culture and confirm the iFKBP insertion and the complete modified FAK gene through DNA sequencing.
BASIC PROTOCOL 2

ANALYSIS OF RapR-KINASE ACTIVITY
Different reaction conditions and specific substrates must be used to assay each kinase. Here, we describe a procedure for biochemical analysis of RapR-FAK activity. Several important controls should be included in this assay. A myc-FAK unmodified kinase construct should be used to test the assay conditions, to compare its activity with RapR-FAK, and to test the effect of rapamycin on the activity of wild-type kinase. A myciFKBP-FAK construct that contains iFKBP at the N-terminus of FAK can be used to assess if introduction of iFKBP at a position other than the insertion loop will affect FAK activity in the absence or presence of rapamycin.
Myc-RapR-FAK-D546R kinase inactive mutant (Asp546Arg mutation) should be used to determine background levels of kinase activity in the immunoprecipitated samples. Purified N-terminal domain of paxillin is used as a substrate in these in vitro kinase assays for FAK. Paxillin is known to be phosphorylated by FAK in the N-terminus. A protocol for purification of the GST-tagged N-terminus of paxillin has been described elsewhere (Lyons et al., 2001) . Transfect-HEK293T cells with myc-RapR-FAK construct.
1. Plate 10 6 HEK293T cells per well into 6-well plates (8 wells total) in DMEM medium/10% FBS and grow in a 37 • C, 5% CO 2 incubator overnight.
2. Using 1:1 ratio co-transfect HEK293T cells with pEGFP-FRB and the following DNA constructs: pmyc-RapR-FAK (two wells), pmyc-FAK (two wells), pmyciFKBP-FAK (two wells), and pmyc-RapR-FAK-D546R (kinase inactive mutant, two wells). Perform transfection using FuGene6 reagent following manufacturer recommendations (2 μg of DNA/3-6 μl FuGene6 per well).
Other equivalent transfection methods can be also used.
Kinase assay 3. Prepare Protein G-coupled agarose beads for incubation with 4A6 anti-myc antibody by transferring 80 μl of bead suspension into a fresh 1.5-ml microcentrifuge tube 4. Wash beads by adding 1 ml of lysis buffer, microcentrifuging 1 min at 4000 × g, room temperature, and removing the supernatant.
5. Resuspend beads in 400 μl of lysis buffer containing 1 mg/ml BSA and add 4 μl of 4A6 antibody.
Use 0.5 μl of antibody per IP.
6. Incubate beads at 4 • C for 1 to 2 hr. Wash beads twice with 1 ml lysis buffer using the technique described in step 4, and resuspend in 400 μl of lysis buffer (50 μl of lysis buffer for each IP). Aliquot 50 μl of beads into fresh 1.5-ml microcentrifuge tubes for incubation with cell lysates.
7. Treat cells with 250 nM rapamycin (added to medium from 1 mM stock) for 1 hr at 37 • C. Treat control samples with an equivalent concentration of ethanol (solvent control). 8. Wash cells with cold PBS on ice by adding and removing ∼3 to 4 ml of PBS per well. Aspirate as much PBS as possible after the wash. Add 300 μl of lysis buffer containing 0.25 μm rapamycin (add from 1 mM rapamycin stock) to each well. For control samples add only the equivalent amount of ethanol to the lysis buffer (0.25% ethanol final).
9. Scrape cells from the plate using a cell scraper, collect cell lysates into 1.5-ml tubes, and microcentrifuge 10 min at 3000 × g, 4 • C. Collect 20 μl of supernatant for protein gel electrophoresis analysis.
Allosteric activation of kinases
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11. Wash beads twice with 0.5 ml of wash buffer and two times with 0.5 ml of kinase buffer (each buffer containing 250 nM rapamycin for the rapamycin-treated samples and the equivalent concentration of ethanol for the controls, 0.25%) using the technique described in step 4. Remove all buffer from beads after last wash.
12. Add 40 μl of kinase buffer with 250 nM rapamycin (added from 1 mM rapamycin stock) to rapamycin-treated samples, and 40 ml of kinase buffer with equivalent concentration of ethanol (0.25% in this particular experiment) to control samples.
Resuspend the beads and transfer 20 μl of each sample into a fresh 1.5 ml tube for the kinase reaction. Add 10 μl of paxillin/ATP mix and incubate 10 min at 37 • C shaking.
13. Stop reaction at the end of the 10-min incubation by adding of 40 μl 2× Laemmli protein sample buffer. Incubate at 95 • to 100 • C 5 min. Cool down. Run on a protein SDS-polyacrylamide gel.
14. Perform western blot (immunoblot) analysis using 4A6 anti-myc antibody for detection of myc-FAK variants, anti-phospho-Tyr31 paxillin antibody for assessment of substrate phosphorylation, and anti-GFP JL8 antibody for detection of GFP-FRB.
BASIC PROTOCOL 3
IMAGING CHANGES IN CELL PHENOTYPE INITIATED BY ACTIVATION OF RapR-KINASES IN LIVING CELLS
In this section, we describe a protocol for activation of RapR-FAK kinase in HeLa cells during live-cell imaging. For these studies we routinely use an Olympus IX-81 microscope equipped with an oil-immersion 40× Olympus UIS2 DIC objective lens, a Photometrix CoolSnap ES2 CCD camera controlled by Metamorph software, and an open heated chamber (Warner Instruments). 2. Co-transfect HeLa cells with 0.5 μg of GFP-FRB plasmid and 1.5 μg of pEGFPRapR-FAK plasmid using 4 μl of FuGene6 according to the manufacturer recommendations. Incubate overnight at 37 • C, 5% CO 2 .
Materials
3. Coat glass coverslips with fibronectin by incubating in 5 mg/ml fibronectin solution in PBS at 4 • C overnight. Wash with PBS.
4. Plate transfected HeLa cells onto fibronectin-coated coverslips. Incubate in DMEM/10%FBS medium for 2 hr at 37 • C, 5% CO 2 .
5. Preincubate mineral oil and L15 Leibovitz medium supplemented with 5% FBS in a tissue culture incubator (37 • C, 5% CO 2 ) for at least 1 hr before imaging.
6. Wash the coverslip with PBS and place it in an Attofluor cell chamber. Add 1 ml of L15 Leibovitz medium with 5% FBS and cover it with 1 ml of mineral oil. 
REAGENTS AND SOLUTIONS
Paxillin/ATP mix
Freshly prepare a solution of 0.1 mM ATP and 0.05 mg/ml purified GST-paxillin N-terminal fragment (DNA construct provided by Dr. Michael D. Schaller of West Virginia University; GST-paxillin N-terminal fragment was purified as described in Lyons et al., 2001) in kinase buffer (see recipe). non-immunosuppressive analogs of rapamycin enabled application of these approaches in live animals (Stankunas et al., 2003) . In our studies, we used similar regulatory elements and demonstrated very tight regulation of RapR-kinase activity not only with rapamycin but also with its non-immusuppressive analogs (Karginov et al., 2010a) .
Critical Parameters
The size of the insertion loop and the linkers connecting iFKBP to the catalytic domain are important for regulation of the kinase. Several alternative constructs should be tested to optimize regulation. One of the most critical parameters for the development of a RapRkinase is the availability of a reliable assay to test kinase activity in vitro and in living cells. Such an assay should be performed with the wild-type form of the kinase prior to testing a RapR-kinase, to ensure accurate and reproducible measurements. In general, an assay should allow you to activate the expressed kinase in living cells and then analyze the activity of the kinase.
Several critical controls should be performed to demonstrate that introduced iFKBP insertion affects only catalytic activity and does not perturb other properties of the kinase. The RapR-kinase localization and interaction with known binding partners should be tested. Other functions such as autoinhibitory regulation should be assessed as well.
The expression system is another important parameter. Ensure that you can achieve sufficient expression levels of your kinase. The presence of tags may affect expression, stability, and localization of the target kinase. For the majority of kinases, transient expression in HEK293T cells should be the simplest option for biochemical characterization. Other cell lines can be used as well, but sufficient transfection efficiency and expression level should be ensured. Stable transfection should be considered for difficult-to-transfect cell lines. In general, expression of GFP-or mCherry-FRB is higher than for RapR-kinase. Thus, a weaker promoter can be used for stable co-expression of the FRB construct.
For each specific biological system, one should always assess the effect of rapamycin alone on the process that is being studied. In our studies, rapamycin had no effect on cell migration and membrane-protrusion formation. If use of rapamycin is problematic, then non-immunosuppressive analogs of rapamycin can be used (iRap, AP21967).
Troubleshooting
Potential problems, and means to address them, include:
iFKBP insertion does not regulate activity. If iFKBP insertion does not affect kinase activity, first test if there is rapamycin-mediated interaction between the modified kinase and FRB. If there is no interaction or it is dramatically reduced, then most likely the insertion perturbed iFKBP structure. This is likely to happen when linkers connecting iFKBP and the catalytic domain are too short, as was demonstrated in our study. If rapamycin successfully induces interaction between the modified kinase and FRB, it indicates that the linkers are too long and iFKBP does not affect the dynamics of the catalytic domain. Alternatively, it is possible that the insertion loop is too long, positioning the iFKBP too far from the β-sheet core structure of the catalytic domain. In this case, short linkers should be used and/or entire insertion loop should be replaced with iFKBP.
There is still significant background activity when the RapR-kinase is in the "off" state. It is possible that iFKBP insertion provides some level of control, but is incapable of inactivating the kinase completely. This may happen if the linkers connecting iFKBP to the catalytic domain are too long and/or if the insertion loop is too large. Complete removal of the insertion loop and/or shorter linkers may improve the regulation. This has been observed in our studies developing RapR-FAK. Alternative problems could be a high background activity level in the particular kinase assay. The background level should be assessed using a kinase-inactive mutant of the RapR-kinase.
Anticipated Results
The method described in this unit should provide guidelines for development of rapamycin-regulated kinases. Using these guidelines, one should be able to identify the site for insertion of iFKBP, develop a strategy for iFKBP insertion, assess the regulation of the modified kinase by rapamycin or its analogs, and analyze the effect of kinase activation on cell behavior.
The successful completion of the described experiments should result in generation of a rapamycin-regulated (RapR) FAK. When cells expressing RapR-FAK are treated with rapamycin, RapR-FAK will be activated, as can be seen using an in vitro kinase assay. There should be no change in the activity of wild-type FAK or iFKBP-FAK control constructs upon treatment with rapamycin. Kinase inactive
